We took a somewhat different perspective from the Morgan et al paper that was published in the CMAJ. We did not see that there would be, in fact, savings for taxpayers under the scenario of a national universal government-run monopoly approach to pharmacare. We saw that there would be substantial costs to absorbing current private sector expenditures on pharmaceutical-related costs, and that if those were absorbed under a federal plan, it would mean that $25 billion would added to the federal budget. If it were absorbed simply—
On June 6th, 2016. See this statement in context.